MTRNR2L5: A Potential Drug Target and Biomarker (G100463289)

Target Name: MTRNR2L5

NCBI ID: G100463289

MTRNR2L5

MTRNR2L5: A Potential Drug Target and Biomarker

MTRNR2L5, a gene located on chromosome 6p21.2, has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders. The MTRNR2L5 gene encodes for a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been linked to several psychiatric and neurological disorders.

The MTRNR2L5 gene has been shown to be involved in the regulation of the expression of several genes involved in neurotransmitter synthesis, release, and uptake, including dopamine, serotonin, and norepinephrine. It has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity, as well as in the modulation of pain perception.

In addition to its potential role in neurotransmission, MTRNR2L5 has also been shown to be involved in the regulation of inflammation and immune response. Studies have shown that MTRNR2L5 can modulate the expression of immune cells and that it is involved in the regulation of inflammatory responses.

Given the involvement of MTRNR2L5 in several psychiatric and neurological disorders, it is a promising target for drug development. Studies have shown that MTRNR2L5 inhibitors have been effective in reducing symptoms of depression, anxiety, and psychosis, as well as in reducing the inflammation associated with these disorders.

In addition to its potential use as a drug target, MTRNR2L5 has also been identified as a potential biomarker for several psychiatric and neurological disorders. Studies have shown that MTRNR2L5 levels are elevated in individuals with major depressive disorder, anxiety disorder, and psychosis, and that these levels are correlated with the severity of these disorders.

Furthermore, MTRNR2L5 has been shown to be involved in the regulation of brain-derived neurotrophic factor (BDNF), a protein that is involved in the maintenance of brain health and is often impaired in individuals with psychiatric and neurological disorders. The regulation of BDNF by MTRNR2L5 has been shown to play a role in the pathophysiology of several psychiatric and neurological disorders, including depression, anxiety, and psychosis.

In conclusion, MTRNR2L5 is a promising target for drug development due to its involvement in the regulation of neurotransmission, inflammation, and immune response, as well as its potential as a biomarker for several psychiatric and neurological disorders. Further research is needed to fully understand the role of MTRNR2L5 in these disorders and to develop safe and effective treatments.

Protein Name: MT-RNR2 Like 5 (pseudogene)

Functions: Plays a role as a neuroprotective and antiapoptotic factor

The "MTRNR2L5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRNR2L5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets